



## Personal information

First name / Surname **Malvina Hoxha**  
Date of birth 22/06/1988  
E-mail m.hoxha@unizkm.al

## Education

2018  
**Visiting Research Scientist at the Medical University of Vienna, Division of Rheumatology, Vienna, Austria**

2016  
**Post- Doc, Department of Preventive Medicine and Public Health, University of Granada (Spain)**

2012-2016  
**PhD in Pharmacological Sciences, Università degli Studi di Milano, Milan, Italy**

*Area of research:* Cardiovascular and Inflammation; COXIB<sub>s</sub> with dual activity: TP antagonist/COXIB; study of Thromboxane Prostanoid receptor (TP) and characterization of its highly functional mutants with respect to homo/heterodimer formation and their regulation by different agonists.

2006-2012  
**Master of Science (Laurea Magistrale) in Pharmacy, Università Cattolica NSBC/ UNIMI. Graduated "Summa cum Laude"**

2004- 2006  
**IB diploma (International Baccalaureate)**  
United World College of South East Asia, **Singapore**

## Actual working position

Full time lecturer; Department of Chemical-Toxicological and Pharmacological Evaluation of Drugs, Faculty of Pharmacy, "Catholic University Our Lady of Good Counsel", Tirana, Albania

**Other Duties** 2019- European Respiratory Society National Delegate (Albania)

**Hoxha M.** Duchenne Muscular Dystrophy: focus on arachidonic acid metabolites. Biomedicine & Pharmacotherapy, Volume 110, February 2019, Pages 796-802. doi.org/10.1016/j.biopha.2018.12.034

**Hoxha M,** Zappacosta B. Nuove frontiere per il trattamento dell'aterosclerosi: PCSK9. Giornale Italiano di Farmacia Clinica. GIFAC 2018;32(4):154-159 | DOI 10.1721/3073.30658

**Hoxha M,** Mikhael AML, Cavanillas AB. Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerebrovascular risk: A systematic review of human clinical trials and in vivo animal studies. Biomedicine & Pharmacotherapy, 2018; 106(2018) 956-965

**Hoxha M.** The role of arachidonic acid mediators in rheumatoid arthritis. Osteoporosis International. 2018; Volume 29, Supplement 1.

**Hoxha M.** The role of arachidonic acid mediators in rheumatoid arthritis. World Congress on osteoporosis, osteoarthritis and musculoskeletal diseases. 19-22 April 2018 Krakow, Poland.

Hodaj A, **Hoxha M,** Zappacosta B. The role of vitamins and homocysteine in thrombophilia..Konferenca e V Farmaceutike. 29-31 March 2018, Tirane, Albania,

Vara-Messler M, Osieki N, Benizio E, **Hoxha M,** Garcia NH. (2017) Eicosapentaenoic acid (EPA, 20:5 w-3) decreases oxidative stress in diabetic rats: A possible role for Nrf-2. XX Lipid Meeting, 07-09 December 2017, Leipzig, Germany

**Hoxha M et.al** A case control study: The role of leukotriene receptor antagonist montelukast in the cardiovascular risk. European Respiratory Journal. 2017; 50: PA1036; DOI: 10.1183/1393003.congress-2017.PA1036

**Hoxha M et.al** A case control study: The role of leukotriene receptor antagonist montelukast in the cardiovascular risk. 27<sup>th</sup> European Respiratory Society Congress, 2017; Milan, Italy

**Hoxha M. et.al.** The role of montelukast in cardiovascular events. Atherosclerosis 263 (2017), e 111-e182. DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.478>

**Hoxha M et.al.** A systematic review on the role of eicosanoid pathways in rheumatoid arthritis. Advances in Medical Sciences, 2017; Aug 14;63(1):22-29.doi: 10.1016/j.advms.2017.06.004

**Hoxha M et.al** A metaanalysis on the role of leukotriene receptor antagonist in reducing the cardiovascular risk. European Academy of Allergy and Clinical Immunology Congress. 2017, 17-21 June 2017, Helsinki, Finland

**Hoxha M et.al** The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field. European Journal of Clinical Pharmacology. 2017; DOI 10.1007/s00228-017-2242-2 [E-pub ahead of print]

**Hoxha M. et.al.** The role of montelukast in cardiovascular events. 85<sup>th</sup> European Atherosclerosis Congress, 23-26 April 2017; Prague, Czech Republic

Vara-Messler M; Pasqualini ME; Comba A; Silva RA; **Hoxha M**; Garcia NH; Valentich MA. La expresión de ER-alfa está asociada a la actividad anti-tumoral de una dieta rica en ácidos grasos omega-3. XXIV Congreso de la Sociedad Argentina de Medicina, 2016; Buenos Aires

**Hoxha M**, et.al. Dizenjimi i gjeneratës së tretë të Antiinflamatorëve: Një qasje e re për Artritin Reumatoid, Konferenca e IV Farmaceutike Shqiptare e Urdhrit të Farmacisteve të Shqipërisë, 27-28 Tetor 2016, Tirana, Albania

**Hoxha M**, et.al. In vitro pharmacological evaluation of multitarget thromboxane prostanoid receptor /COX-2 agents: A possible strategy to solve the cardiovascular issues of COXIBs., *Atherosclerosis* 252 (2016) e1ee196

**Hoxha M**, et.al. In vitro pharmacological evaluation of multitarget thromboxane prostanoid receptor /COX-2 agents: A possible strategy to solve the cardiovascular issues of COXIBs., 84<sup>th</sup> European Atherosclerosis Congress, 29 May-1 June 2016; Innsbruck, Austria

**Hoxha M**, et.al. In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition. *Pharmacological Research*; 2016; 103:132-43. doi: 10.1016/j.phrs.2015.11.012.

Messler M.V, Buccellati.C, Pustina.L, Folco.C, Rovati.GE, **Hoxha M**. "A potential role of PUFAs and COXIBs in cancer chemoprevention", *Prostaglandins and other lipid mediators*, 2015 Apr 20. pii: S1098-8823(15)00045-3. doi: 10.1016/j.prostaglandins.2015.04.003. [Epub ahead of print]

**Hoxha M**, et.al. "A possible new avenue to solve the cardiovascular issues of COXIBs", European PhD School on "Bioactive Lipids", 23-27 November 2014, Pescara, Italy

**Hoxha M**, et.al. "A new gateway for Rheumatoid Arthritis: COXIBs with a safety cardiovascular profile" University of Milan, 03 June 2014, Milan, Italy

**Hoxha M**, et.al. "A new gateway for Rheumatoid Arthritis: COXIBs with a safety cardiovascular profile", International Conference on Pharmacology and Pharmaceutical Sciences, 14-15 April 2014, Venice, Italy.

**Hoxha M**, et.al. "Optimizimi i profilit të sigurisë së COXIB-ëve: Derivatet e Lumirakoksibit me aktivitet të dyfishtë: Frenues të ciklooksigenazës-2 dhe antagonist të receptorit të tromboksanit A2", II National Pharmaceutical Conference, 2-3 November 2013, Tirana

**Hoxha M**, et.al. "A Multitarget approach to optimize the safety profile of COXIBs: Lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity", University of Milan, 17 July 2013, Milan, Italy

**Hoxha M**, et.al. "A Multitarget approach to optimize the safety profile of COXIBs: Lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity". International Congress of Bio-Medical Sciences, 1-4 May 2013, Tirana



Bertinaria M, Shaikh MA, Buccellati C, Cena C, Rolando B, Lazzarato L, Fruttero R, Gasco A, **Hoxha M**, Capra V, Sala A, Rovati GE. "Designing Multitarget Anti-Inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward dual thromboxane antagonists-COX-2 inhibitors" ChemMedChem 2012 August 2, 7, 1647-1660. PMID: 22865828

**Hoxha. M.** "Bologna Process, where does it go?" European Pharmaceutical Student Association (EPSA) Newsletter , volume 16, 2nd Edition, pg 16, January 2009

**Hoxha. M.** "Bilingualism" International Bilingualism Conference, 2006; Singapore

**Didactic Activity** **UNIVERSITY OUR LADY OF GOOD COUNSEL, TIRANA (2013-onwards):** Lecturer of Pharmacology/Albanian Pharmaceutical Legislation

**OTHER DIDACTIC ACTIVITIES:** University of Milan (Cultore della Materia "Pharmacognosy and Pharmacology", Faculty of Pharmacy); **Albanian Order of Pharmacists** (Guest Lecturer).

**Awards** 2017: Winner of the Excellence Award from the Austrian Academy of Science  
2017: Young Investigator Fellowship obtained from the European Atherosclerosis Society  
03 June 2014: Best Oral Presentation, Next Step 5, Department of Pharmacological Sciences, University of Milan, Italy  
2009: Research award in memory of Professor Elena Sottocornola  
20 April 2006: "Bilingual Award" obtained from United World College of South East Asia, Singapore

**Accademic Experiences**  
**Trainings** 2017: External Expert for QKEV (National Center of Continuous Education)  
2016: Participation to the "Diet and prevention of cardiovascular disease" programme, Innsbruck, Austria  
2014: International School of Pharmacology on "Eicosanoids", 2-7 September 2014, Erice, Sicily  
2007- 2014: EPSA member (European Pharmaceutical Student Association)  
October 2013: InnoTal Project: Selected among PhD students from 260 Lombardian Schools of PhD ("Talent for global innovation: Promoting the human capital of Excellence"), Milan, Italy

**Language Skills**

- Mother tongue: Albanian
- English (understanding (C1); speaking (C1); writing (C1))
- Italian (understanding (C1); speaking (C1); writing (C1))
- Spanish (understanding (B2); speaking (A2); writing (A2))
- French (understanding (B2); speaking (B1); writing (B1))

**Additional Information**

- Volunteer work in KK Women's and Children's Hospital, Singapore
- Member of "Initiative for Peace", Global concern group, Singapore
- Volunteer work in rising the funds for tsunami victims, Singapore
- Volunteer work in "Mercy Centre", Bangkok, Thailand
- Volunteer work in orphanage, Ho Chi Minh, Vietnam